Effects of the melatonin MT-1/MT-2 agonist ramelteon on daytime body temperature and sleep
RR Markwald, TL Lee-Chiong, TM Burke, JA Snider… - Sleep, 2010 - academic.oup.com
Study Objectives: A reduction in core temperature and an increase in the distal-proximal skin
gradient (DPG) are reported to be associated with shorter sleep onset latencies (SOL) and …
gradient (DPG) are reported to be associated with shorter sleep onset latencies (SOL) and …
Drug insight: the use of melatonergic agonists for the treatment of insomnia—focus on ramelteon
SR Pandi-Perumal, V Srinivasan, B Poeggeler… - Nature Clinical Practice …, 2007 - nature.com
Melatonin, a chronobiotic that participates in the control of the circadian system, is known for
its sleep-promoting effects, which include shortening of sleep latency and lengthening of …
its sleep-promoting effects, which include shortening of sleep latency and lengthening of …
Pilot study on the effect of ramelteon on sleep disturbance after traumatic brain injury: preliminary evidence from a clinical trial
A Lequerica, N Jasey, JNP Tremont… - Archives of physical …, 2015 - Elsevier
Objective To investigate the effect of ramelteon on sleep and daytime functioning among
individuals with traumatic brain injury (TBI). Design A double-blind, placebo-controlled study …
individuals with traumatic brain injury (TBI). Design A double-blind, placebo-controlled study …
Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials
M Moline, G Zammit, J Yardley, K Pinner… - Postgraduate …, 2021 - Taylor & Francis
Objectives Residual next-day effects of sleep-promoting drugs are common and an
important safety issue. Lemborexant is a dual orexin receptor antagonist approved in the …
important safety issue. Lemborexant is a dual orexin receptor antagonist approved in the …
Ramelteon and improved insomnia in alcohol-dependent patients: a case series
KJ Brower, DA Conroy, ME Kurth… - Journal of Clinical …, 2011 - jcsm.aasm.org
In this case series of 5 alcohol-dependent patients with insomnia who had initiated
abstinence, a 4-week course of ramelteon 8 mg nightly was associated with markedly …
abstinence, a 4-week course of ramelteon 8 mg nightly was associated with markedly …
Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3). A randomized controlled trial
PK Schweitzer, R Rosenberg, GK Zammit… - American Journal of …, 2019 - atsjournals.org
Rationale: Primary treatment of obstructive sleep apnea can be accompanied by a
persistence of excessive sleepiness despite adherence. Furthermore, effectiveness of sleep …
persistence of excessive sleepiness despite adherence. Furthermore, effectiveness of sleep …
Effects of long‐term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia
G Richardson, S Wang‐Weigand - … : Clinical and Experimental, 2009 - Wiley Online Library
Objective To evaluate the effects of ramelteon, an MT1/MT2 melatonin receptor agonist used
to treat insomnia, on endocrine function in adults with chronic insomnia. Methods This was a …
to treat insomnia, on endocrine function in adults with chronic insomnia. Methods This was a …
Fresh from the pipeline: Ramelteon.
Abstract Ramelteon (Rozerem; Takeda), a melatonin receptor agonist, was approved by the
US FDA for the treatment of insomnia in July 2005. In contrast to other widely used drugs for …
US FDA for the treatment of insomnia in July 2005. In contrast to other widely used drugs for …
Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy
PK Schweitzer, KP Strohl, G Mayer… - Journal of Clinical …, 2021 - jcsm.aasm.org
Study Objectives: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved
in the United States and European Union to treat excessive daytime sleepiness in patients …
in the United States and European Union to treat excessive daytime sleepiness in patients …
A randomized phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity
P De Boer, WC Drevets, H Rofael… - Journal of …, 2018 - journals.sagepub.com
Background: Seltorexant is a potent and selective antagonist of the orexin-2 receptor that is
being developed for the treatment of insomnia and major depressive disorder. Aims: The …
being developed for the treatment of insomnia and major depressive disorder. Aims: The …